MSC-sTRAIL showed more prominent anti-tumor effects than MSC-FL-TRAIL when used combined with AKT inhibitors in LNCaP, C4-2B, and PC3 cells (in vitro). The gene discussed is TNFSF10; the disease is neoplasm.